Adalimumab for the treatment of hidradenitis suppurativa/acne inversa

被引:32
作者
Zouboulis, Christos C. [1 ,2 ,3 ,4 ,5 ]
机构
[1] Dessau Med Ctr, Dept Dermatol, Auenweg 38, D-06847 Dessau, Germany
[2] Dessau Med Ctr, Dept Venereol, Auenweg 38, D-06847 Dessau, Germany
[3] Dessau Med Ctr, Dept Allergol, Auenweg 38, D-06847 Dessau, Germany
[4] Dessau Med Ctr, Dept Immunol, Auenweg 38, D-06847 Dessau, Germany
[5] European Hidradenitis Suppurativa Fdn eV, Dessau, Germany
关键词
Hidradenitis suppurativa; acne inversa; treatment; adalimumab; biologics; NECROSIS-FACTOR-ALPHA; EUROPEAN S1 GUIDELINE; LABEL CLINICAL-TRIAL; RHEUMATOID-ARTHRITIS; ACNE INVERSA; TNF-ALPHA; RANDOMIZED-TRIAL; DOUBLE-BLIND; FC-RECEPTOR; THERAPY;
D O I
10.1080/1744666X.2016.1221762
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Hidradenitis suppurativa/acne inversa (HS) is a chronic, inflammatory, recurrent, debilitating skin disease of the hair follicle that usually presents after puberty with painful, deep-seated, inflamed lesions in the apocrine gland-bearing areas of the body, most commonly the axillae, inguinal and anogenital regions. A mean disease incidence of 6.0 per 100,000 persons-years and a varying prevalence of 0.05-1% have been reported worldwide.Areas covered: This manuscript summarizes the current evidence on chemistry, pharmacodynamics, pharmacokinetics, as well as clinical efficacy, safety and tolerability of the currently approved biologic drug adalimumab in the treatment of active moderate to severe HS in adults. Active, inflammatory lesions are expected to improve following 12 weeks of adalimumab treatment. The therapeutic response is greater following the registered weekly adalimumab (40mg sc) administration in all clinical studies compared with the other treatments. Safety results were consistent with the known adalimumab safety profile.Expert commentary: Active, inflammatory lesions of HS are expected to respond to weekly administered adalimumab treatment. However, non-inflammatory, scarring lesions cannot respond to it. In such cases a combination treatment with radical surgery is required.
引用
收藏
页码:1015 / 1026
页数:12
相关论文
共 78 条
  • [1] A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa
    Amano, Masahiro
    Grant, Annika
    Kerdel, Francisco A.
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2010, 49 (08) : 950 - 955
  • [2] Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles
    Anderson, PJ
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2005, 34 (05) : 19 - 22
  • [3] [Anonymous], COCHRANE DATABASE SY
  • [4] Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy
    Arenbergerova, Monika
    Gkalpakiotis, Spyridon
    Arenberger, Petr
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2010, 49 (12) : 1445 - 1449
  • [5] Management of Hidradenitis Suppurativa with Biological Therapy: Report of Four Cases and Review of the Literature
    Bahillo Monne, Constanza
    Honorato Guerra, Silvia
    Schoendorff Ortega, Cristina
    Gargallo Quintero, Ana Belen
    [J]. DERMATOLOGY, 2014, 229 (04) : 279 - 287
  • [6] Blanco R, 2009, ARCH DERMATOL, V145, P580, DOI 10.1001/archdermatol.2009.49
  • [7] Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review
    Blok, J. L.
    van Hattem, S.
    Jonkman, M. F.
    Horvath, B.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (02) : 243 - 252
  • [8] Regulation of tumour necrosis factor signalling: live or let die
    Brenner, Dirk
    Blaser, Heiko
    Mak, Tak W.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2015, 15 (06) : 362 - 374
  • [9] Moderate to severe hidradenitis suppurativa treated with biological therapies
    Chinniah, Niranthari
    Cains, Geoffrey David
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2014, 55 (02) : 128 - 131
  • [10] Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States
    Cosmatos, Irene
    Matcho, Amy
    Weinstein, Rachel
    Montgomery, Michael O.
    Stang, Paul
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (03) : 412 - 419